Deleted in liver cancer (DLC1), a Rho GTPase-activating protein, was observed to be differentially expressed in oral squamous cell carcinoma in comparison with normal tissues using tissue proteomics. In the current study, we investigated the clinical significance of loss of DLC1 expression in different stages of development of oral squamous cell carcinoma to determine its potential as a biomarker for oral dysplasia and prognosis of oral squamous cell carcinoma. Immunohistochemical analysis of DLC1 expression was carried out in oral squamous cell carcinoma patients (n ¼ 214), dysplasia (n ¼ 51), hyperplastic squamous mucosa (n ¼ 45), and histologically normal oral tissues (n ¼ 80), and correlated with clinicopathological parameters and disease prognosis over 91 months for oral squamous cell carcinomas. Loss of DLC1 expression was observed in oral squamous cell carcinoma (64%), oral dysplasia (31%), hyperplastic squamous mucosa (22%), and normal mucosa (16%). Significant loss of DLC1 expression was observed in oral squamous cell carcinomas as compared with dysplasia (Po0.001, odds ratio ¼ 3.8, 95% CI ¼ 2.0-7.3), suggesting it may be an important event involved in cancer progression. Among oral squamous cell carcinomas, the loss of DLC1 expression was significantly associated with poor prognosis (P ¼ 0.021, hazards ratio (HR) ¼ 1.8, 95% CI ¼ 1.1-2.9). Multivariate analysis revealed loss of DLC1 (P ¼ 0.023, HR ¼ 2.1, 95% CI ¼ 1.2-3.9) and histopathological grade (P ¼ 0.015, HR ¼ 1.7, 95% CI ¼ 1.1-2.7) to be independent predictors for disease-free survival in oral squamous cell carcinoma patients in comparison with known prognostic factors, viz. tumor stage, nodal status, and overall stage. Loss of DLC1 expression emerged as an important biomarker for predicting patients diagnosed with oral dysplasia at high risk of transformation upon future validation in longitudinal studies. Loss of DLC1 expression is a poor prognostic marker for oral squamous cell carcinoma patients.
Oral squamous cell carcinoma ranks as the sixth leading cause of cancer death worldwide, developing annually in B560 000 individuals and causing over 300 000 deaths. 1 Oral squamous cell carcinoma is often preceded by clinically well-defined lesions such as leukoplakia, causally linked with chronic exposure of the oral mucosa to carcinogens/growth promoters in tobacco and alcohol. [2] [3] [4] Although DNA aneuploidy and grade of dysplasia have been used as predictors for progression of dysplasia to cancer, these are not accurate predictors for evaluating the risk of malignancy. [5] [6] [7] [8] Furthermore, oral squamous cell carcinoma patients also show poor clinical outcome owing to loco-regional recurrence, metastasis, or development of second primary tumors, despite advances in combined multi-modality therapy. Such outcomes clearly reflect our lack of understanding of the molecular mechanisms underlying development and progression of oral cancer. Therefore, risk stratification using clinical and pathological criteria is inadequate. 9 Thus, identification of biomarkers that can differentiate high-risk lesions from more benign lesions is of critical importance for early intervention in high-risk patients. In addition, major thrust is being laid on assessing the clinical applicability of biomarkers in predicting response to therapy, recurrence, survival, and overall prognosis. 10 The use of biomarkers will hopefully transform clinical practice by including cancer diagnosis based on molecular markers as a complement to histopathology, and aid in better management of the disease.
Deleted in liver cancer (DLC1) gene encodes a Rho GTPase-activating protein (RhoGAP), and is a potent tumor suppressor gene in several major human cancers. [11] [12] [13] [14] [15] Loss or downregulation of DLC1 expression, caused by genomic alterations or epigenetic modifications, frequently leads to activation of Rho GTPase, a key mediator of human oncogenesis. 11, 12, 14, [16] [17] [18] [19] [20] [21] [22] Transcriptional reactivation of silenced DLC1 gene in tumor cells suppresses their proliferation and migration, induces apoptosis in vitro, and inhibits tumorigenicity and metastasis in vivo. 16, 21, [23] [24] [25] [26] [27] [28] Initially, the effects of DLC1 as a tumor suppressor were attributed to its RhoGAP activity, which has a significant role in cell growth, cytokinesis, morphogenesis, cell motility, trafficking, organization of cell cytoskeleton, transformation, and metastasis. 21, 29 Subsequently, RhoGAPindependent tumor-suppressive mechanisms have also been identified. 21, 30, 31 Several binding partners of DLC1 have been identified, including members of the tensin family of focal adhesion proteins (eg, tensin1, tensin2, and C-terminal tensin like (cten)), p120RasGAP, elongation factor 1A1 (EF1A1), and S100A10, which further delineates its mechanism and its role in inhibiting cancer cell migration, proliferation, and metastasis. 30, [32] [33] [34] [35] DLC1 gene silencing promotes pro-angiogenic responses through upregulation of vascular endothelial growth factor, accompanied by the accumulation of hypoxia-inducible factor 1 alpha and its nuclear localization. 36 Since its discovery, compelling evidence has accumulated that demonstrates a role for DLC1 as a bonafide tumor suppressor gene in different types of human cancers. [11] [12] [13] [14] [15] In our previous study, we used isobaric tags for relative and absolute quantitation (iTRAQ), and multidimensional liquid chromatography/tandem mass spectrometry for comparing the protein expression profile of human oral squamous cell carcinoma and normal tissues.
37 DLC1 was identified as one of the differentially expressed proteins in oral squamous cell carcinoma, and in view of its role as a tumor suppressor protein, reduced expression in these tumors is an important finding. In-depth studies are warranted to determine its clinical significance in oral squamous cell carcinoma. Here in this study, we hypothesized that loss of DLC1 expression may occur in early stages of development of oral squamous cell carcinoma and impacts disease progression. To verify this hypothesis, we have analyzed its expression in tissue specimens from different stages of oral squamous cell carcinoma development, ie, hyperplastic squamous mucosa, dysplasia, and oral squamous cell carcinoma, and compared its expression in histologically normal oral mucosa by immunohistochemistry using a polyclonal antibody against DLC1, and correlated our findings with clinicopathological parameters and disease prognosis. The histopathological grading of epithelial dysplasia was based on evaluation of architectural and cytological changes following the WHO classification. 3, 5 For each case, the pathologist recorded the grade and details of the criteria on which the decision was based. Oral lesions were classified into two groups: (a) hyperplastic squamous mucosa and (b) dysplasia (mild, moderate, or severe). Histologically confirmed oral normal epithelia, oral hyperplastic squamous mucosa, dysplasia, and oral squamous cell carcinomas as revealed by H&E staining were used for immunohistochemistry. 37 Patient demographic, clinical, and pathological data were recorded in a pre-designed performa as described previously. 38 The information documented included clinical TNM staging (tumor, node, and metastasis based on the Union International Center le Cancer TNM classification of malignant tumors 1998), site of the lesion, histopathological grade, age, gender, treatment, and tobacco consumption habits.
Materials and methods

Patients
Follow-Up Study
Of the 214 oral squamous cell carcinomas, 181 patients (85%) could be followed in the head and neck cancer follow-up clinic at regular time intervals, while 33 patients (15%) were lost to follow-up. Survival status of the oral squamous cell carcinoma patients was verified and updated from the records of the Tumor Registry, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, as of December 2010. Oral squamous cell carcinoma patients were monitored for a maximum period of 91 months (range 1-91 months; mean 24 months and median 16 months). As per the hospital protocol, oral squamous cell carcinoma patients with T 1 and T 2 tumors were treated with radical surgery alone, whereas the majority of patients with T 3 and T 4 disease were treated with radical surgery followed by postoperative radical radiotherapy as described by us. 38 The patients were revisited clinically on a regular basis and the time to recurrence was recorded. If a patient died, the survival time was censored at the time of death; the medical history, clinical examination, and radiological evaluation were used to determine whether the death had resulted from recurrent cancer (relapsing patients) or from any other causes. Disease-free survivors were defined as patients free from clinical and radiological evidence of local, regional, or distant relapse at the time of the last follow-up. All the 181 patients had undergone surgery as the primary treatment. Of these 181 patients, post-surgical treatment details were available for 172 patients. Of these 172 patients, 129 patients (75%) underwent radiotherapy and 43 patients had no radiotherapy treatment.
Loco-regional relapse/death was observed in 86 of 181 (47.5%) patients monitored during the followup. Ninety-five patients who did not show recurrence were alive until the end of the follow-up period. Only disease-free survival was evaluated in the present study, as the number of deaths due to disease progression did not allow a reliable statistical analysis. Disease-free survival was expressed as the number of months from the date of surgery to loco-regional relapse.
Immunohistochemistry
Paraffin-embedded sections (5 mm) of human oral nonmalignant tissues (n ¼ 80), hyperplastic squamous mucosa (n ¼ 45), dysplasia (n ¼ 51), and oral squamous cell carcinomas (n ¼ 214) were collected on gelatin-coated slides. Immunohistochemistry conditions were optimized. In brief, the sections were deparaffinized in xylene, hydrated in gradient alcohol, and pretreated in a microwave oven for 15 min in citrate buffer (0.01 M, pH ¼ 6.0) for antigen retrieval. The sections were incubated with hydrogen peroxide (0.3% v/v) in methanol for 30 min to quench the endogenous peroxidase activity, followed by blocking with 1% bovine serum albumin to preclude nonspecific binding. Thereafter, the slides were incubated with goat polyclonal anti-DLC1 antibody (1 mg/ml, ab21200, Abcam, Cambridge, MA, USA) for 16 h at 4 1C. The primary antibody was detected using the streptavidin-biotin complex using the Dako LSAB plus kit (Dako CYTOMATION, Glostrup, Denmark) and diaminobenzidine as the chromogen. 39 All procedures were carried out at room temperature unless otherwise specified. Slides were washed with Tris-buffered saline (0.1 M, pH ¼ 7.4), 3-5 times after every step. Finally, the sections were counterstained with Mayer's hematoxylin and mounted with D.P.X mountant. In the negative control tissue sections, the primary antibody was replaced by isotypespecific nonimmune mouse IgG. A section from normal liver tissue was used as a positive control in each batch of immunohistochemistry. The sections were evaluated by light microscopic examination.
Evaluation of Immunohistochemical Staining
Each slide was evaluated for DLC1 immunoreactivity using a scoring system for both staining intensity and the percentage of positive epithelial cells. Immunostaining was evaluated in randomly selected five areas of the tissue section. For DLC1 protein expression, sections were scored as positive if epithelial cells showed cytoplasmic expression when observed independently by three of us (SCT, JK, and SDG), who were blinded to the clinical outcome (the slides were coded, and the scorers did not have previous knowledge of the local tumor burden, lymphonodular spread, and grading of the DLC1 loss correlates with poor prognosis tissue samples). The tissue sections were scored based on the percentage of DLC1 immunopositive cells as: 0-10% ¼ 0; 10-30% ¼ l; 30-50% ¼ 2; 50-70% ¼ 3; and 70-100% ¼ 4. Sections were also scored on the basis of staining intensity as negative ¼ 0; mild ¼ 1; moderate ¼ 2; and intense ¼ 3. Finally, a total score was obtained by adding the score of percentage positivity and intensity. The scoring by all three observers (SCT, JK, and SDG) was discrepant in about 8% cases and a consensus on the final result was reached by re-evaluation of these slides and discussion.
Statistical Analysis
The immunohistochemical data were subjected to statistical analysis using the SPSS 17.0. software (Chicago). Sensitivity and specificity were calculated and quantified using receiver operating characteristic (ROC) analysis. The predictive value (PV) describes the proportion of correctly classified cases. Based on sensitivity and specificity values for DLC1 expression, a cutoff p3 was defined as criterion for loss of DLC-l expression. The relationships between DLC1 protein loss and clinicopathological parameters were tested using w 2 and Fisher's exact test. Two-sided P-values were calculated and Po 0.05 was considered to be significant. Prognostic significance of DLC1 expression was assessed by Kaplan-Meier survival and multivariate Coxproportional hazards regression analysis. The systematic and rigorous assessment of positive PVs and negative PVs for prognostic biomarker was carried out as described earlier by us. 38 Heagerty and Zheng method of time-dependent receiver operator curve and area under the curve was used for the survival model. 40 The R-package risk set ROC was used to apply the standard Cox regression output and obtain estimates of time-dependent sensitivity and specificity, and time-dependent receiver operator curves. In the Cox regression models, the other covariates that were included are age, tumor stage, nodal status, overall stage, gender, histopathological grade, treatment, and tobacco consumption habits.
Results
Immunohistochemical Analysis of DLC1 Expression in Oral Hyperplastic Squamous Mucosa, Dysplasia, and Oral Squamous Cell Carcinoma
Of the 80 histologically normal tissues analyzed, 13 tissues (16%) showed loss of DLC1 expression in cytoplasm of epithelial cells (Table 1 and Figure 1a) . Notably, 12 of these 13 cases showing loss of DLC1 expression were paired normal tissues obtained from oral squamous cell carcinoma patients as compared with 1 of 13 non-paired normal oral tissues (Table 1) . Of the 45 oral hyperplastic squamous mucosa analyzed, 10 cases (22%) showed loss of DLC1 protein expression in comparison with normal tissues (Figure 1b) , while a large proportion of the hyperplastic tissues (78%) showed cytoplasmic immunostaining (Table 2 and Figure 1c) . A total of 16 of 51 (31%) cases with histological evidence of dysplasia showed loss of DLC1 expression in comparison with normal tissues (Table 3 and Figure 1e ). Among the oral squamous cell carcinomas, 136/214 cases (64%) showed loss of DLC1 expression in tumor cells (Table 4 and Figure 1f) . Notably, loss of DLC1 expression was significant in oral squamous cell carcinomas in comparison with dysplasia (Po0.001, odds ratio (OR) ¼ 3.8, 95% CI ¼ 2.0-7.3) and normal oral tissues (Po0.001, OR ¼ 8.9, 95% CI ¼ 4.7-17.3). No immunostaining was observed in tissue sections used as negative controls where the primary antibody was replaced by isotype-specific IgG (Figure 1h ), while the positive control (normal liver tissue) showed cytoplasmic expression of DLC1 protein (Figure 1i ). No significant association was observed between loss of DLC1 expression and various clinicopathological parameters of oral squamous cell carcinoma (Table 4) , dysplasia (Table 3) , or hyperplastic squamous mucosa (Table 2) .
ROC curve analysis was used to determine the potential of loss of DLC1 expression as a biomarker to distinguish hyperplastic squamous mucosa, dysplasia, and oral squamous cell carcinomas from normal oral epithelium (Table 5 ). The positive PVs for DLC1 loss in hyperplastic squamous mucosa, (Table 5) .
DLC1 Loss as a Predictor of Disease Progression and Prognosis
The follow-up data of 181 oral squamous cell carcinoma patients for up to 91 months were used to assess the prognostic value of DLC1 for predicting cancer recurrence in oral squamous cell carcinoma patients after completion of primary treatment. (Table 6 ). These findings clearly Figures 2b and c) . Hence, these findings underscore the potential of DLC1 loss as a marker for predicting recurrence in oral squamous cell carcinomas.
Discussion
Early detection of head and neck cancer can decrease both morbidity and mortality associated with this malignancy. However, screening for head and neck cancer in premalignant stages and identifying oral premalignant lesions (dysplasia) at high risk of transformation is currently unpredictable. [5] [6] [7] [8] 41, 42 Furthermore, the histological diagnosis of dysplasia can be subjective and is thus prone to considerable variations in interpretations among pathologists. Thus, molecular biomarkers capable of identifying the subset of lesions likely to progress to cancer are required to eliminate this clinical diagnostic dilemma. In view of these considerations, our study clearly demonstrated significant loss of DLC1 expression in oral squamous cell carcinomas in comparison with dysplasia, suggesting loss of DLC1 might be an important event in progression of dysplasia toward malignancy. Further, our study underscores the need for longitudinal follow-up studies of the patients diagnosed with dysplastic lesions to determine the potential of DLC1 as a biomarker for predicting the risk of developing malignancy in future. Large-scale studies are needed to validate our findings. Nonetheless, our study assumes importance as the first clinical study revealing loss of DLC1 expression as a biomarker for oral dysplasia. This finding is further supported by other reports demonstrating loss of DLC1 expression to be an early event in development and progression of lung, liver, and renal cancers. [43] [44] [45] 
DLC1 loss correlates with poor prognosis
Importantly in our study, Kaplan-Meier survival analysis showed that loss of DLC1 expression is associated with poor prognosis of oral squamous cell carcinoma patients. Further, DLC1 loss also emerged as an independent prognostic marker in multivariate analysis, in comparison with the known clinical and pathological factors for oral squamous cell carcinomas including age, gender, site, histopathological grade, tumor stage, nodal status overall stage, and treatment. Further, analysis of the predictive potential of DLC1 loss revealed its utility as a marker to identify aggressive oral squamous cell carcinomas, supporting the association observed by both the Kaplan-Meier analysis and logistic regression analysis. Our results are further supported by the reports that suggest loss of DLC1 expression enhances angiogenesis, cell migration, adhesion, proliferation, and has an essential role in cancer progression. 16, 22, 36, 46 DLC1 abrogates cell motility and functions as a suppressor of metastasis in cancer cells 21, 26, 31, 47 as well as inhibits proliferation and induces apoptosis. 21, 26, 28, 31, 45, 47, 48 Conversely, depletion of DLC1 in cells enhances growth and motility potential. 49, 50 DLC1 is widely DLC1 loss correlates with poor prognosis carcinoma. 56, 57 Recent evidence showed both genomic deletion and aberrant promoter methylation of DLC1 in hepatocellular, prostate, and non-small cell lung carcinomas, which could occur early in multiple stages of carcinogenesis. 43, 44, 58 Other mechanisms could possibly be involved in the regulation of DLC1 activity in tumor tissues with normal expression of DLC1. The RhoGAP domain has been shown to be functionally important to the biological activities of DLC1 tumor suppressor. Loss of Rho-GAP activity via mutation in RhoGAP domain 25, 31 or by binding to 14-3-3 proteins has shown to regulate the tumor suppressor activity of DLC1 and facilitates signaling by active Rho. 59 Phorbol-ester-induced activation of protein kinase C and protein kinase D stimulates association of DLC1 with the phosphoserine/phosphothreonine binding 14-3-3 adaptor proteins via recognition motifs that involve Ser327 and Ser431. 59 In summary, significant loss of DLC1 expression was observed in oral squamous cell carcinomas suggesting an important role in development and progression to malignancy. Further, oral squamous cell carcinoma patients showing loss of DLC1 expression showed poor prognosis. However, largescale longitudinal studies are warranted to evaluate the potential of DLCl as an indicator of progression risk in dysplasia and its role in development and progression in tumorigenesis.
